Revisiting the issue of malignancy risk in systemic lupus erythematosus.

Ann E. Clarke, Rosalind Ramsey-Goldman, Sasha Bernatsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Certain cancers occur more frequently in systemic lupus erythematosus (SLE) as compared with the general population, as recent data substantiates. The risk appears to be most heightened for lymphoma. Several pathogenic mechanisms may explain these observations, although little is definitively known. One particular concern relates to whether cancer risk in SLE is increased by medication exposures. Cooperative efforts to evaluate this have been undertaken by the Systemic Lupus International Collaborating Clinics and the Canadian Network for Improved Outcomes in Systemic Lupus research groups. This and other works in progress will, it is hoped, considerably advance the knowledge regarding the association between autoimmune diseases and malignancy.

Original languageEnglish (US)
Pages (from-to)476-481
Number of pages6
JournalCurrent rheumatology reports
Issue number6
StatePublished - Dec 2005

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Revisiting the issue of malignancy risk in systemic lupus erythematosus.'. Together they form a unique fingerprint.

Cite this